Nursing home residents could largely profit from the second COVID-19 vaccine booster, based on a latest study published this week. 
 
The study published within the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report Friday indicated that the second mRNA COVID-19 booster shots were effective in stopping hospitalizations and deaths amongst nursing home residents. 

After analyzing data from 200 nursing homes across 19 states, the researchers behind the study said the shot was 90% effective at stopping COVID-related deaths and 74% effective at stopping severe cases that led to hospitalizations. 

The team sought to check the relative effectiveness of the second booster dose of mRNA vaccines with a single-booster dose distributed amongst eligible nursing home residents in 19 states. 

“Efforts must be made to make sure that nursing home residents remain up up to now with beneficial booster doses of COVID-19 vaccines,” the CDC wrote in response to the findings. 

Meanwhile, the team noted that the study results highlighted the importance of continued efforts to make sure that nursing home residents are up up to now on the beneficial vaccine booster doses, including the newly authorized bivalent COVID-19 vaccine. 

The study checked out cases between March 29 and July 25. This era was when the BA.5 omicron subvariant became the dominant strain within the country. 

White House COVID-19 response coordinator Ashish Jha responded to the study findings by writing on Twitter, “One other study showing large advantages of vaccines soon after 2nd boosters authorized.”

He continued, “Nursing home residents who got them were 90% less prone to die than residents who didn’t. Wow. For this reason we’re so focused on ensuring folks, particularly the high risk, get the most recent vaccine.”

The White House has urged eligible individuals to get the bivalent booster shots once they turn out to be available of their areas to avoid one other surge in COVID cases in the autumn and winter, as per The Hill. 

As previously reported, the CDC beneficial the brand new bivalent boosters from Pfizer and Moderna early this month since they showed efficacy against the BA.4 and BA.5 omicron subvariants.